Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 65


Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries.

Herlihy N, Hutubessy R, Jit M.

Health Aff (Millwood). 2016 Feb;35(2):227-34. doi: 10.1377/hlthaff.2015.1411.


Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?

Jit M, Hutubessy R.

Appl Health Econ Health Policy. 2016 Jun;14(3):245-52. doi: 10.1007/s40258-016-0224-7.


Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach.

Sundaram N, Schaetti C, Merten S, Schindler C, Ali SM, Nyambedha EO, Lapika B, Chaignat CL, Hutubessy R, Weiss MG.

BMC Public Health. 2016 Jan 14;16:36. doi: 10.1186/s12889-016-2710-0.


A systematic review of the social and economic burden of influenza in low- and middle-income countries.

de Francisco Shapovalova N, Donadel M, Jit M, Hutubessy R.

Vaccine. 2015 Nov 27;33(48):6537-44. doi: 10.1016/j.vaccine.2015.10.066. Epub 2015 Oct 25. Review.


A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.

Ngabo F, Levin A, Wang SA, Gatera M, Rugambwa C, Kayonga C, Donnen P, Lepage P, Hutubessy R.

Vaccine. 2015 Dec 16;33(51):7357-63. doi: 10.1016/j.vaccine.2015.10.022. Epub 2015 Oct 29.


Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O.

Pharmacoeconomics. 2016 Mar;34(3):227-44. doi: 10.1007/s40273-015-0335-2.


The broader economic impact of vaccination: reviewing and appraising the strength of evidence.

Jit M, Hutubessy R, Png ME, Sundaram N, Audimulam J, Salim S, Yoong J.

BMC Med. 2015 Sep 3;13:209. doi: 10.1186/s12916-015-0446-9. Review.


Evaluation of Health-Related Quality of Life among Patients with Cervical Cancer in Indonesia.

Endarti D, Riewpaiboon A, Thavorncharoensap M, Praditsitthikorn N, Hutubessy R, Kristina SA.

Asian Pac J Cancer Prev. 2015;16(8):3345-50.


Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.

Jauregui B, Garcia AG, Bess Janusz C, Blau J, Munier A, Atherly D, Mvundura M, Hajjeh R, Lopman B, Clark AD, Baxter L, Hutubessy R, de Quadros C, Andrus JK.

Vaccine. 2015 May 7;33 Suppl 1:A28-33. doi: 10.1016/j.vaccine.2014.10.090.


Estimating costs of care for meningitis infections in low- and middle-income countries.

Portnoy A, Jit M, Lauer J, Blommaert A, Ozawa S, Stack M, Murray J, Hutubessy R.

Vaccine. 2015 May 7;33 Suppl 1:A240-7. doi: 10.1016/j.vaccine.2014.11.061. Review.


Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national Expanded Programme on Immunization.

Jit M, Dang TT, Friberg I, Hoang VM, Pham Huy TK, Walker N, Nguyen VC, Tran ND, Toda K, Hutubessy R, Fox K, Nguyen TH.

Vaccine. 2015 May 7;33 Suppl 1:A233-9. doi: 10.1016/j.vaccine.2014.12.017.


Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study.

van der Putten IM, Evers SM, Deogaonkar R, Jit M, Hutubessy RC.

BMC Public Health. 2015 Apr 10;15:356. doi: 10.1186/s12889-015-1638-0.


Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".

Newall AT, Jit M, Hutubessy R.

Pharmacoeconomics. 2014 Dec;32(12):1247. doi: 10.1007/s40273-014-0232-0. No abstract available.


Methods for Health Economic Evaluations of Vaccines - Results from an International Expert-Workshop.

Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote AU, Greiner W, Hanquet G, Harder T, Hutubessy R, Jit M, Knol M, Kuhlmann A, von Kries R, Levy-Bruhl D, Perleth M, Postma MJ, Salo H, Siebert U, Wasem J, Weidemann F, Wichmann O.

Value Health. 2014 Nov;17(7):A552. doi: 10.1016/j.jval.2014.08.1803. Epub 2014 Oct 26. No abstract available.


Identifying the Broader Value of Vaccines in Low and Middle Income Countries.

Van der Putten IM, Hiligsmann M, Paulus AT, Hutubessy R, Evers SM.

Value Health. 2014 Nov;17(7):A548. doi: 10.1016/j.jval.2014.08.1783. Epub 2014 Oct 26. No abstract available.


Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.

Jit M, Brisson M, Portnoy A, Hutubessy R.

Lancet Glob Health. 2014 Jul;2(7):e406-14. doi: 10.1016/S2214-109X(14)70237-2. Epub 2014 Jun 9.


Reassessing the value of vaccines.

Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, Griffiths U, Hansen P, Hashmani FN, Hutubessy R, Jamison DT, Jha P, Jit M, Johnson H, Laxminarayan R, Lee BY, Mhatre S, Mills A, Nordström A, Ozawa S, Prosser L, Silver K, Benn CS, Standaert B, Walker D.

Lancet Glob Health. 2014 May;2(5):e251-2. doi: 10.1016/S2214-109X(13)70170-0. Epub 2014 Apr 23. No abstract available. Erratum in: Lancet Glob Health. 2014 Jun;2(6):e322.


Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.

Levin A, Wang SA, Levin C, Tsu V, Hutubessy R.

PLoS One. 2014 Jun 26;9(6):e101114. doi: 10.1371/journal.pone.0101114. eCollection 2014.


Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.

Newall AT, Jit M, Hutubessy R.

Pharmacoeconomics. 2014 Jun;32(6):525-31. doi: 10.1007/s40273-014-0162-x.


Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation.

Kotsopoulos N, Connolly MP, Postma MJ, Hutubessy RC.

Vaccine. 2013 Nov 4;31(46):5430-4. doi: 10.1016/j.vaccine.2013.09.002. Epub 2013 Sep 18.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk